Computational TROP2 Biomarker Predicts Outcomes for Datopotamab Deruxtecan in TROPION-Lung01 Phase III Trial

An exploratory analysis of the TROPION-Lung01 Phase III trial revealed that TROP2, as measured by AstraZeneca’s advanced computational pathology platform—quantitative continuous scoring (QCS)—was a predictor of clinical outcomes in patients…

Read MoreComputational TROP2 Biomarker Predicts Outcomes for Datopotamab Deruxtecan in TROPION-Lung01 Phase III Trial